Free Trial

Patrick Mauro Investment Advisor INC. Buys 65,440 Shares of Pfizer Inc. (NYSE:PFE)

Pfizer logo with Medical background

Patrick Mauro Investment Advisor INC. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 387,607 shares of the biopharmaceutical company's stock after purchasing an additional 65,440 shares during the quarter. Pfizer accounts for 5.4% of Patrick Mauro Investment Advisor INC.'s holdings, making the stock its 5th largest position. Patrick Mauro Investment Advisor INC.'s holdings in Pfizer were worth $9,822,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Clarity Asset Management Inc. purchased a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC raised its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Pfizer in the first quarter worth $28,000. Bernard Wealth Management Corp. purchased a new stake in Pfizer in the fourth quarter worth approximately $30,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer during the 4th quarter worth $32,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock traded down $0.02 during mid-day trading on Thursday, reaching $24.59. 47,333,190 shares of the company were exchanged, compared to its average volume of 41,969,404. The firm's 50-day simple moving average is $23.99 and its two-hundred day simple moving average is $24.77. The firm has a market cap of $139.83 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.82 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.99%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PFE. Bank of America lifted their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. BMO Capital Markets reduced their target price on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group upped their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Berenberg Bank cut their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $28.55.

Read Our Latest Stock Analysis on Pfizer

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines